Axxam enters into Drug Discovery Collaboration with Vivozon for CNS Indications
May 12, 2020
Axxam announces a collaboration with Vivozon Inc. with the aim to support Vivozon in the development of innovative small molecule drugs for the treatment of patients with unmet CNS medical needs. Thanks to its expertise in early phase discovery biology, Axxam began the collaboration with Vivozon by providing access to a panel of cell-based assays to test Vivozon’s compounds on targets of interest, thereby supporting Vivozon’s scientists in the hit-to-lead program and drug discovery research.